Welcome: Guest | Site Use Options | Register | Login |

Xanthus Life Sciences Inc

Xanthus Life Sciences Inc

Profile last edited on: 7/31/2008
300 Technology Square
Cambridge, MA 02139
  (617) 225-0522
Business Identifier: Personalized cancer drugs
Public Profile:
In May of 2008, Xanthus Life Sciences Inc was acquired by British firm Antisoma plc. Xanthus focuses on oncology development and aims to commercialize drugs with a test enabling personalized dosing of chemotherapeutic agents. Xanthus is focused to development and commercialization of anticancer and other compounds in conjunction with its phenotyping technology. Xanthus was founded on the belief that drugs are given to a person not to a disease. All people are different and hence require different treatments. Xanthus is dedicated to developing customized dosing regimens for drug therapies that are responsive to individual patients requirements. Xanthus intends to improve the practice of medicine through the development of customized dosing regimens

 Synopsis: Awardee Business Condition
Year Founded First SBIR Year Date of Last Award
Employee Range VC funded? IP Holdings
Revenue Range Private/Public Exchange/Symbol :
 Most Recent SBIR Projects
Year Phase Agency Dollars Project Title
Acetylator-based Individualized Dosing of Amonadife

Unlock access

To unlock access to all SBIR-STTR company Profiles, a FREE site registration is required. Click here to register or login if you already have an account

Smart Office Options

SBIR firms in the news


Is this YOUR Company?

Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached

Do you know about this Awardees?

Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Contact information

Innovation Development Institute, LLC

   45 Beach Bluff Avenue, Suite 300
     Swampscott,  MA 01907-1542

  Tel:  (781) 595-2920